- •Drug Product Development for the Back of the Eye
- •Preface
- •Contents
- •Contributors
- •1.1 Introduction
- •1.2 A Strategic Overview of Drug Delivery Systems
- •1.3 Specific Approaches to Drug Delivery for the Posterior Segment
- •1.3.1 The Influence of Physicochemical Properties on Drug Delivery and Pharmacokinetics
- •1.3.2 The Chosen Route of Administration
- •1.3.3 Location of the Target Tissue
- •1.3.4 Potency of the Drug
- •1.3.5 Need for Continuous or Pulsatile Delivery
- •1.3.6 Duration of Drug Delivery Necessary to Induce and Maintain Efficacy
- •1.3.7 Type of Drug Delivery System Selected
- •1.3.8 Pharmacokinetic (PK) Properties of the Drug
- •1.3.9 Local and Systemic Toxicity of the Drug and its Metabolites
- •1.3.10 Previous Ocular Use of Excipients
- •1.3.11 Development and Strategic Team Input
- •References
- •2.1 Introduction
- •2.2 Posterior Segment as a Sampling Site
- •2.3 Principle of Microdialysis
- •2.3.1 Extraction Efficiency/Recovery
- •2.4.1 Anesthetized Animal Models
- •2.4.2 Conscious Animal Model
- •2.5 Vitreal Pharmacokinetics in Animals Other than Rabbits
- •2.6 Summary
- •References
- •3.1 Commercial Fluorophotometer
- •3.2 Normal Human Subject and Rabbit Ocular Fluorescence
- •3.3 Fluorophotometry Applications
- •3.3.1 Tear Turnover Rate (%/min)
- •3.3.2 Corneal Epithelial Cell Layer Permeability Methodologies
- •3.3.3 Eye Bath Technique
- •3.3.4 Single Drop Technique to Measure Epithelial Permeability
- •3.3.5 Eye Bath Technique to Measure Epithelial Permeability
- •3.4 Clinical Applications of Fluorophotometry
- •3.5.1 Transscleral Pathways
- •3.5.2 Suprachoroidal Injection
- •3.6 Retrobulbar Fluorescein Injection
- •3.7 Intravenous Fluorescein Injection In Vivo
- •3.8 Ocular Uptake of Fluorescein from Topical Eye Drops
- •References
- •4.1 Introduction
- •4.1.1 Role of the Blood-Retinal Barrier as a Dynamic Interface
- •4.1.2 Potential Approach of Blood-Retinal Barrier-Targeted Systemic Drug Delivery to the Retina
- •4.2.1 Amino Acid-Mimetic Drugs
- •4.2.2 Monocarboxylic Drugs
- •4.2.3 Nucleoside Analogs
- •4.2.4 Folate Analogs
- •4.2.5 Organic Cationic Drugs
- •4.2.6 Opioid Peptides and Peptidomimetic Drugs
- •4.2.7 Antioxidants
- •4.2.7.1 Vitamin C
- •4.2.7.2 Vitamin E
- •4.2.7.3 Cystine
- •4.2.8 Miscellaneous Protective Compounds
- •4.2.8.1 Creatine
- •4.2.8.2 Taurine
- •4.3.1 Organic Anion Transporter 3 (OAT3, SLC22A8)
- •4.3.3 P-Glycoprotein (ABCB1)
- •4.3.4 Multidrug Resistance-Associated Proteins (ABCCs)
- •4.3.6 ABCAs
- •4.4 Conclusions and Perspectives
- •References
- •5.1 Introduction
- •5.2 Drug Distribution
- •5.2.1 Drug Distribution from the Anterior Ocular Surface to the Posterior Segment
- •5.2.2 Studies of Trans-Corneal and Periocular Drug Delivery to the Retina
- •5.2.2.1 The Uvea-Scleral Route
- •5.3 Eye Drops for Posterior Segment Diseases in the Clinic
- •5.4 Summary
- •References
- •6.1 Introduction
- •6.2 Vitreous Anatomy
- •6.2.1 The Inner Limiting Membrane
- •6.3 The Vitreous As a Drug Reservoir
- •6.4 Flow Processes in the Vitreous
- •6.4.1 Flow Patterns
- •6.4.2 Injection and Hydrostatic Effects
- •6.4.3 Diffusion
- •6.4.4 Convective Flow
- •6.5 Clearance Pathways from the Vitreous Compartment
- •6.5.1 Charge and Collagen Interaction
- •6.5.2 Aqueous Clearance
- •6.5.3 Retinal Clearance
- •6.6 Transfer Through the Vitreoretinal Border
- •6.6.1 The Role of the Blood–Retinal Barrier
- •6.6.1.1 Amino Acid Transport
- •6.6.1.2 P-Glycoprotein
- •6.6.1.3 Organic Cationic Transporters
- •6.6.1.4 Organic Anion Transporters
- •6.6.1.5 Other Transporters
- •6.7 The Ageing Vitreous
- •6.7.1 Underlying Mechanisms of Vitreous Degeneration
- •6.7.2 Physical Changes Involved in the Ageing Vitreous
- •6.7.2.1 Pre-Clinical Model of Ageing Vitreous
- •6.7.2.2 Effects of Vitreous Liquefaction on Intravitreal Drug Delivery
- •6.7.3 Vitrectomised Eyes
- •6.7.3.1 Intravitreal Drug Distribution and Clearance in Silicone Oil
- •6.7.4 Role of Ocular Movements in Disordered Vitreous
- •6.8 Concluding Remarks
- •References
- •7.1 Introduction
- •7.2 Drug Delivery to Posterior Segment Ocular Tissues
- •7.3 Scleral Structure and Drug Delivery
- •7.4 Scleral Permeability: Initial Studies
- •7.5 Sustained-Release Delivery In Vitro
- •7.6 In Vivo Studies
- •7.7 Conclusions and Future Directions
- •References
- •8.1 Introduction
- •8.2 Background
- •8.3 Posterior Segment Delivery
- •8.4 Transscleral and Intrascleral Drug Delivery
- •8.5 Suprachoroidal Drug Delivery
- •8.6 Summary
- •References
- •9.1 Introduction
- •9.2 Nonbiodegradable Ocular Drug Delivery Systems
- •9.2.1 Retisert
- •9.2.2 Ocusert
- •9.2.3 Vitrasert
- •9.2.4 I-vation
- •9.2.5 Iluvien
- •9.2.6 Nonbiodegradable Matrix Implants
- •9.2.6.2 Punctal Plugs
- •9.3 Medical Applications for Biodegradable Polymers
- •9.3.3 Poly(Ortho Esters)
- •9.3.4 Polyanhydrides
- •9.5.1 Ozurdex™
- •9.5.2 Surodex
- •9.5.3 Verisome
- •9.5.4 Lacrisert
- •9.6.1 Poly(Lactic Acid)-Based Implants
- •9.6.2 PLGA-Based Implants
- •9.6.5 Poly(Ortho Ester)-Based Implants
- •9.6.6 Polyanhydride-Based Implants
- •9.6.7 Other Biodegradable Polymer-Based Implants
- •9.7 Conclusions
- •References
- •10.1 Introduction
- •10.2 Manufacturing of Microparticles
- •10.3 Characterization of Microparticles
- •10.3.1 Morphological Characterization of Microparticles
- •10.3.2 Particle Size Analysis and Distribution
- •10.3.3 Infrared Absorption Spectrophotometry (IR)
- •10.3.4 Differential Scanning Calorimetry (DSC)
- •10.3.5 X-Ray Diffraction
- •10.3.6 Gel Permeation Chromatography (GPC)
- •10.3.7 Determination of Drug Loading Efficiency
- •10.3.8 “In Vitro” Release Studies
- •10.3.8.1 Additives in Microspheres
- •10.4 Sterilization of Microparticles
- •10.5 Calculation of the Dose of Microparticles for Injection
- •10.6 Injectability Studies
- •10.7 In Vivo Studies
- •10.7.1 In Vivo Injection of Microparticles
- •10.7.2 Ocular Disposition and Cellular Uptake
- •10.7.3 Tolerance of Microparticles
- •10.7.4 In Vivo Degradation of PLA and PLGA Microparticles
- •10.8 In Vitro and In Vivo Correlation
- •10.9 Microparticles for the Treatment of Posterior Segment Diseases. Animal Models and Human Studies
- •10.9.1 Proliferative Vitreoretinopathy (PVR)
- •10.9.2 Uveitis
- •10.9.3 Age-Related Macular Degeneration (AMD)
- •10.9.4 Diabetic Retinopathy
- •10.9.5 Macular edema
- •10.9.6 Acute Retinal Necrosis (ARN)
- •10.9.7 Cytomegalovirus (CMV) Retinitis
- •10.9.8 Choroidal Neovascularization
- •10.9.9 Diseases Affecting the Optic Nerve
- •10.9.11 Microparticles in Retinal Repair
- •10.10 Conclusions
- •References
- •11.1 Introduction
- •11.2 Nanoparticles
- •11.2.1 Polymer Nanoparticles
- •11.2.2 Liposomes and Lipid Nanoparticles
- •11.2.3 Micelles
- •11.2.4 Protein Nanoparticles
- •11.2.5 Carbohydrate Nanoparticles
- •11.2.6 Dendrimers
- •11.2.7 Combination Nanosystems
- •11.3 Using Nanotechnology to Improve Ocular Therapeutics
- •11.3.1 Improving Patient Compliance
- •11.3.2 Increasing Drug Retention and Sustained Release
- •11.3.3 Increasing Permeability and Tissue Partitioning
- •11.3.4 Targeting Nanotherapies
- •11.3.5 Intracellular Trafficking
- •11.4 Alternative Approaches to Improve Ocular Therapeutics
- •11.5 Conclusion
- •References
- •12.1 Introduction
- •12.2 Hydrogel Technology
- •12.6 Future Directions
- •References
- •13.1 Introduction
- •13.2 General Design Considerations
- •13.2.1 Administration Site
- •13.2.2 Body Design
- •13.2.3 Port Design
- •13.2.4 Vacuum and Pressure
- •13.2.5 Flushing and Fluid Replacement
- •13.2.5.1 Active Pumps
- •13.2.5.2 Passive Systems
- •13.2.5.3 Solid Refill
- •13.2.6 Contamination Potential
- •13.3 Historical Influences
- •13.3.1 Infusion Pumps
- •13.3.2 Glaucoma Drainage Devices
- •13.3.3 Pioneering of Refill Procedure in the Eye
- •13.4 Ophthalmic Refillable Devices
- •13.4.1 Invasiveness and Refilling Frequency
- •13.4.2 Intravitreal Delivery Through the Pars Plana
- •13.4.3 Episcleral Implantation for Trans-Scleral Delivery
- •13.4.4 Subretinal and Suprachoroidal Implantation
- •13.4.5 Lens Capsule Delivery
- •13.5 Conclusions
- •References
- •14.1 Introduction
- •14.2 Current Methods of Drug Delivery to the Eye
- •14.3 Improved Methods of Drug Delivery to the Eye Using Microneedles
- •14.3.1 Intrastromal Delivery to the Cornea Using Coated Microneedles
- •14.3.3 Suprachoroidal Delivery Using Hollow Microneedles
- •14.4 Microneedle Types and Other Applications
- •14.4.1 Poke and Apply
- •14.4.2 Coat and Poke
- •14.4.3 Poke and Release
- •14.4.4 Poke and Flow
- •14.5 Discussion
- •14.6 Conclusion
- •References
- •15.1 Introduction
- •15.1.1 General Mechanisms of Iontophoretic Drug Delivery
- •15.1.2 The Shunt Pathway
- •15.1.3 The Flip–Flop Gating Mechanism
- •15.1.4 Electro-Osmosis
- •15.2 Ocular Drug Delivery: The Past and the Future
- •15.3 Ophthalmic Applications of Iontophoresis
- •15.3.1 Transconjunctival Iontophoresis
- •15.3.1.1 Transconjunctival Iontophoresis of Antimitotics
- •15.3.1.2 Transconjunctival Iontophoresis of Anesthetics
- •15.3.2 Transcorneal Iontophoresis
- •15.3.2.1 Transcorneal of Fluorescein Iontophoresis for Aqueous Humor Dynamic Studies
- •15.3.2.2 Transcorneal Iontophoresis of Antibiotics
- •15.3.2.3 Transcorneal Iontophoresis of Antiviral Drugs
- •15.3.2.4 Other Drugs for Transcorneal Iontophoresis
- •15.3.2.5 Is Transcorneal Iontophoresis Safe?
- •15.4 Transscleral Iontophoresis
- •15.4.1 Transscleral Iontophoresis of Antibiotics
- •15.4.2 Transscleral Iontophoresis of Antiviral Drugs
- •15.4.3 Transscleral Iontophoresis of Anti-Inflammatory Drugs
- •15.4.3.1 Aspirin
- •15.4.3.2 Glucocorticoids
- •15.4.3.3 Transscleral Iontophoresis of Carboplatin
- •15.4.3.4 Is Transscleral Iontophoresis Safe?
- •15.4.3.5 Transscleral Iontophoresis for High Molecular Weight Compounds and Proteins
- •15.4.3.6 Clinical Application of Transscleral Iontophoresis
- •15.5 Applications of Iontophoresis to Ocular Gene Therapy
- •15.6 Future Developments
- •References
- •16.1 Introduction
- •16.2 Background
- •16.2.1 Intravitreal Injections
- •16.2.2 Impact of Genetics
- •16.3 Better Tools for Delivery and Treatment
- •16.3.1 Barriers to Success
- •16.3.2 Physics-Based Approaches
- •16.3.2.1 Physical Methods to Deliver Drugs to a Target Cell in the Posterior Segment
- •16.3.2.2 History of Electrical Fields in Medicine
- •16.3.2.3 Safety Concerns with Electric Fields
- •16.3.2.4 Definitions of Electric Field Methods
- •16.3.2.5 Advantages of Electric Fields for DNA Transfection vs. Viral Mediated DNA Delivery
- •16.3.2.6 Problems of In Vivo Electric Field Applications
- •16.3.2.7 Possible Strategies to Improve Electric Field-Mediated Drug Delivery
- •16.3.3 Experiences with Iontophoresis
- •16.3.3.1 Examples of Iontophoresis
- •16.3.3.2 Summary of the Strengths and Weaknesses of Iontophoresis
- •16.3.4 Experiences with Electroporation
- •16.3.4.1 Examples of Electroporation in Living Animals
- •16.3.4.2 Strengths and Weaknesses of Electroporation
- •16.4 Outstanding Issues in Electric Fields for the Delivery of Drugs
- •16.5 Summary
- •References
- •17.1 Introduction
- •17.2 Routes of Protein Administration
- •17.2.1 Topical
- •17.2.2 Intracameral
- •17.2.3 Intravitreal
- •17.2.4 Periocular (Transscleral)
- •17.2.5 Suprachoroidal
- •17.2.6 Subretinal
- •17.2.7 Systemic
- •17.3 Advantages and Challenges of Protein Delivery
- •17.4 Current Development Strategies
- •17.4.1 Pure Protein
- •17.4.2 PEGylation
- •17.4.4 Liposomes
- •17.4.5 Stem Cells
- •17.4.6 Implants
- •17.5 Case Studies
- •17.6 Ophthalmic Protein Formulation Development
- •17.6.1 Protein Biosynthesis
- •17.6.2 Preformulation Studies
- •17.6.3 Selection of Excipients
- •17.6.4 Optimization of Process Variables
- •17.7 Specifications and Regulatory Guidelines
- •17.8 Conclusions
- •References
- •18.1 Need for Suspension Development for the Back of the Eye
- •18.2 Background
- •18.3 Development of Drug Suspensions Intended for the Back of the Eye
- •18.3.1 Drug Suspensions
- •18.3.1.1 Physical Pharmacy Principles that Explain the Stability and Formulation of Suspensions
- •18.3.1.2 Formulation Methodology
- •18.3.1.3 Manufacturing Process
- •18.3.2 Factors To Be Considered in Suspension Development for the Back of the Eye
- •18.3.2.1 Formulation Development and Evaluation
- •18.3.2.2 In Situ Forming Suspensions, Selection of Drug Form for Suspension, and Polymeric Microparticle Suspension
- •18.3.2.3 Clinical Studies on Safety
- •18.4 Conclusions
- •References
- •19.1 Introduction
- •19.2 Drug Product Approval Process
- •19.3 Considerations for Back of the Eye Treatments
- •19.4 Adaptive Trial Design
- •19.5 Drug-Device Combinations
- •19.6 Product Summary Basis of Approval Reviews
- •19.6.1 OZURDEX™
- •19.6.2 LUCENTIS™
- •19.7 Summary
- •References
- •20.1 Background
- •20.2 FDA Endpoints
- •20.3 Endpoints for Neovascular Age-Related Macular Degeneration (Table 20.1)
- •20.4 FDA Guidelines for Other Retinal Diseases
- •20.5 Endpoint for Geographic Atrophy
- •20.6 Endpoint for Retinal Vein Occlusion
- •20.7 Future Endpoints
- •References
- •21.1 Introduction
- •21.2 Ocular Physiology and Pathology
- •21.2.1 Ocular Inflammation
- •21.2.2 Neovascularization
- •21.2.3 Degeneration
- •21.3 Current Therapies for Key Back of the Eye Disorders
- •21.3.1 Age-Related Macular Degeneration
- •21.3.1.1 Pathophysiology
- •21.3.1.2 Therapeutics Either in Current Use or in Clinical Trials
- •21.3.1.3 Current Research Focused on Identifying New Targets
- •21.3.2 Diabetic Retinopathy
- •21.3.2.1 Pathophysiology
- •21.3.2.2 Therapeutics Either in Current Use or in Clinical Trials
- •21.3.3 Retinopathy of Prematurity
- •21.3.3.1 Pathophysiology
- •21.3.3.2 Therapeutics Either in Current Use and in Clinical Trials
- •21.3.4 Degenerative Conditions
- •21.3.4.1 Pathophysiology
- •21.3.4.2 Therapeutics Either in Current Use or in Clinical Trials
- •21.3.5 Opportunistic Infections
- •21.3.5.1 Pathophysiology
- •21.3.5.2 Therapeutics Either in Current Use or in Clinical Trials
- •21.3.6 Autoimmune Disease
- •21.3.6.1 Pathophysiology
- •21.3.6.2 Therapeutics Either in Current Use or in Clinical Trials
- •21.4 Conclusion
- •References
- •22.1 Bile Acids as Anti-Apoptotic Neuroprotectants
- •22.3 Potential Need for Local Delivery of Bile Acids as Neuroprotectants
- •22.4 Preliminary Studies of Ocular Delivery of Bile Acids
- •22.5 Conclusion
- •References
- •Index
136 |
C.G. Wilson et al. |
6.5 Clearance Pathways from the Vitreous Compartment
It is classically accepted that drug substances administered intravitreally are cleared either anteriorly to the aqueous chamber or posteriorly to the retina as shown in Fig. 6.7. As has been mentioned earlier, the meridonal flow described by Fowlkes is also important but even this is overly simplistic when considering poorly soluble suspensions which may aggregate following an initial dispersion phase. Following injection of suspensions of triamcinolone to the rabbit eye, aggregates of drug were seen by fundus photography on the floor of the posterior chamber at 2–3 days and up to at least 15 days post-injection (Scholes et al. 1985). In patients who had undergone vitrectomy and had received injections of crystalline cortisol, the material was observed in the macular region in two patients, wherafter it disappeared at 2 months with sequalae (Jonas et al. 2000). From these observations, it is clear that settling of a suspension and subsequent aggregation should result in marked regional differences in distribution of drug over the inner retina.
6.5.1 Charge and Collagen Interaction
Gene delivery to the vitreous offers the prospect of a longer acting and more effective therapy. Early attempts to utilise complexes of DNA and cationic carriers including polyethyleneimine, poly-L-lysine and 1,2-Dioleyl-3-trimethyl ammonium-propane- based (DOTAP) liposomal vehicles revealed that vitreous humour decreased the cellular uptake of these vehicles by an retinal pigmented epithelium (RPE) cell line D407 in cultured cells (Pitkänen et al. 2003). To a lesser extent, this behaviour was also seen in hyaluronate solutions and it was proposed that the human vitreous would be a diffusional barrier for cationic DNA complexes. Peeters et al. demonstrated that intravitreal injections of polystyrene microparticles stick within the mucus, probably by charge interaction with the collagen fibres of the vitreous (Peeters et al. 2005). By formulation of the DNA lipoplexes with increasing amounts of distearoyl
Fig. 6.7 (a) Diffusion towards the posterior and retina (b), forward clearance through the anterior chamber and (c), meridonal flow as described by Fowlkes
6 Principles of Retinal Drug Delivery from Within the Vitreous |
137 |
phosphatidylethanolamine polyethylene glycol (DSPE-PEG) to systems which are smaller than 500 nm, no binding of the coated lipoplexes to vitreal collagen strands was observed above a content of 16.7 mol% and a clear relationship between the DSPE-PEG concentration and aggregation could be observed in the micrographs.
6.5.2 Aqueous Clearance
Friedrich’s group has shown that injection position and volume has significant influence on clearance kinetics of model compounds fluorescein and fluorescein glucuronide (Friedrich et al. 1997a, b). Different injection sites (including behind the lens, at the hyaloid membrane, central injection and injection next to the retina) were found to influence the measured retinal permeability of fluorescein from 1.94 × 10−5 up to 3.50 × 10−5 cm/s. Thus the site of the intravitreal injection of fluorescein is predicted to influence distribution and permeability through the retina. In addition, it was calculated that the mean concentration remaining in the vitreous at 24 h varied up to a factor of 3.8-fold dependent on initial location of the smaller volume of 15 mL. It was also shown that increasing the volume from 15 to 100 mL reduced the magnitude of these changes to approximately 2.5-fold at 24 h (Friedrich et al. 1997a).
The rapid turnover of aqueous humour in the anterior chamber is the main motive force for forward clearance. All compounds injected intravitreally can be removed through this bulk flow system. The majority of materials can effortlessly move across the hyaloid membrane; the central anterior position of the lens being the main barrier to this forward movement (Xu et al. 2000; Worst and Los 1995). Thompson and Glaser showed that the flux of 20 and 70 kDa dextran from the vitreous into the anterior chamber increased significantly after extracapsular lensectomy with posterior capsulotomy (Thompson and Glaser 1984). In addition, according to the study performed by Stepanova et al., the transport mechanism present at the lens epithelium generates uni-directional flow that moves fluids towards the retina rather than the anterior chamber (Stepanova et al. 2005). Therefore, materials tend to move around the edge of the lens, instead of diffusing across the highly packed 20 nm collagen meshwork (Worst and Los 1995). Substances that successfully enter the anterior chamber are subsequently removed along with aqueous humour by the trabecular and uveoscleral outflow (Cunha-Vaz 1997).
The aqueous drainage at the anterior chamber generates a sustained “sink condition” for intravitreally administered substances, resulting in the formation of a concentration gradient, originating from the injection pocket, that spreads across the vitreous cavity. Maurice illustrated a clearance process parallel to the posterior capsule of the lens with the lowest concentration located at the hyaloid membrane gradually increasing towards the retina (Araie and Maurice 1991).
Typically, hydrophilic and larger molecules that are not able to exit through the retina are removed via the anterior route. Atluri and Mitra investigated the vitreal disposition of short-chain aliphatic alcohols with varying degrees of lipophilicity in
138 |
C.G. Wilson et al. |
rabbits using ocular microdialysis techniques. Their findings reveal that methanol achieved the highest concentration at the anterior chamber, whereas the concentration of the more lipophilic 1-heptanol was undetectable (Atluri and Mitra 2003). Araie and Maurice have also shown that, as opposed to fluorescein which is smaller and lipophilic, larger and hydrophilic molecules such as fluorescein glucuronide and fluorescein isothiocyanate dextran have poor retinal penetration. A steep concentration gradient from the vitreous to the posterior chamber was noted and flux through the retina was small indicating loss through the aqueous route (Araie and Maurice 1991). In addition, a small human study utilising samples taken from the aqueous humour, demonstrated that the anterior elimination pathway is important for intravitreal clearance of the steroid, triamcinolone (Beer et al. 2003).
If we exclude transporter effects and phagocytosis, the retinal barrier of the inner eye should be problematic for large molecules with low flux which would to be removed by the aqueous system (Atluri and Mitra 2003; Urtti 2006). A relatively small biopharmaceutical, an oligonucleotide with an approximate molecular weight of 7 kDa, exhibited rapid anterior clearance following intravitreal injection, with less than 7% remaining after 7 days (Dvorhik and Marquis 2000). A study of a larger sized biopharmaceutical, rituximab, in rabbits, suggested that clearance of rituximab occurred via the aqueous route. It was suggested that Rituximab diffuses through the vitreous, between the lens and ciliary body, into the anterior chamber for removal (Kim et al. 2006). Similarly, removal via aqueous humour is thought to represent the predominant clearance pathway of bevacizumb, following intravitreal administration in man (Krohne et al. 2008). Bakri et al. described the clearance kinetics of intravitreal bevacizumab in Dutch-belted rabbits using a non-compartmental model and concluded that bevacizumab was cleared through the anterior pathway with an estimated intravitreal half-life of 4.32 days (Bakri et al. 2007).
6.5.3 Retinal Clearance
The posterior elimination pathway has been proposed to be the primary route for small and lipophilic molecules. Once removed from the retina, materials will be subsequently transported away by the choroidal blood flow. If melanin binding is significant, accumulation in the melanocytes of the uveal tract will occur. The RPE is able to remove material by passive diffusion through the paracellular and/or transcellular routes. In vitro, the retinal permeability is 8–20 times higher for lipophilic than hydrophilic molecules, suggesting a higher efficiency of the transcellular pathway (Pitkänen et al. 2005).
Inflammation of the RPE, encountered in patients with endophthalmitis, damages retinal pump function thereby decreasing the intravitreal half-life of molecules eliminated by this system (Ficker et al. 1990). The RPE therefore forms an important component of the blood-retinal barrier and contains retinal glial cells
6 Principles of Retinal Drug Delivery from Within the Vitreous |
139 |
and the endothelium of retinal blood vessels (Cunha-Vaz 1997). An early study by Mosley (1981) modelled the movement of [133Xe] xenon from the vitreous through the retina, using samples taken from the vortex vein and concluded that the radioisotope was cleared from the vitreous, to the retina and into the choroid circulation with a mean transit time of 27 min. A pharmacokinetic model of data from a rabbit study suggested the antiviral used in the treatment of cytomegalovirus retinitis, ganciclovir, is eliminated across the retinal surface (Tojo et al. 1999). In addition, following intravitreal administration of memantine, high concentrations were found in the choroid and RPE, suggesting posterior elimination (Koeberle et al. 2003).
The size of antibody fragments begins to approach nanoparticulate dimensions and therefore data from nanoparticulate movement might be a useful predictor of large anti-VEGF agents. Sakurai et al. showed that particles of sizes 200 nm and below can transverse the retina but 2 mm particles were found to mainly clear through the trabecular meshwork (Sakurai et al. 2001). Pitkänen et al. have also reported that the permeability of carboxyfluorescein (376 Da) was 35 times higher as compared to FITC-dextran 80 kDa (Pitkänen et al. 2005). In contrast, data obtained by Dias and Mitra showed that FITC-dextran at a molecular weight of 38.9 kDa was predominantly removed from the vitreous through the retina, an observation attributed to the possible presence of channel-mediated transport mechanism at the retina for large and hydrophilic molecules (Dias and Mitra 2000). A comparison between the characteristics of forward and retinal clearance is illustrated in Table 6.1.
Table 6.1 Comparison between the forward and retinal routes of clearance
|
Forward clearance |
Retinal clearance |
|
|
|
Site of activity |
Aqueous chamber |
Retina |
Barrier system |
Blood–aqueous barrier, lens |
Blood–retina barrier |
“Sink” condition |
Aqueous humour turnover |
Choroidal blood flow |
Diffusional contour |
Parallel to the posterior capsule |
Parallel to the retina surface |
|
of the lens |
|
Active transport |
Ciliary epithelium and iris |
Retinal pigment epithelium and |
mechanism |
|
retinal capillaries |
Drug molecule |
Hydrophilic |
Lipophilic |
Examples |
Aminoglycosides (Barza et al. |
b-lactam antibiotics (Barza et al. |
|
1983; Cobo and Forster 1981) |
1983) |
|
Fluorescein glucuronide (Araie and |
Fluorescein (Araie and Maurice |
|
Maurice 1991) |
1991) |
|
Fluorescein dextran (Araie and |
1-Heptanol (Atluri and Mitra 2003) |
|
Maurice 1991) |
|
|
Methanol (Atluri and Mitra 2003) |
Dexamethasone |
|
|
Brimonidine |
|
|
Cu2+ ions (Bito and Baroody 1987) |
